^
Association details:
| Biomarker: | EGFR G719C + EGFR S768I |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations
Published date:
08/05/2022
Excerpt:
The 59-year-old male patient with smoking history for more than 40 years was pathologically diagnosed as adenosquamous carcinoma...Uncommon EGFR mutations, including G719C and S768I, were identified in tumor sample. The patient received 20 cycles of Pembrolizumab (PD-1 inhibitor) treatment (Figure 8). During treatment, the patient maintained partial response (PR), and the primary and metastatic lesions were controlled for more than 16 months.
DOI:
https://doi.org/10.3389/fonc.2022.92289
